Mersana Therapeutics has signed an agreement with EMD Serono, Merck’s biopharmaceutical division, to co-develop next-generation antibody-drug conjugates (ADCs).

Mersana’s Fleximer technology will be used to generate ADCs for multiple undisclosed targets. The two companies will test a variety of ADCs by using Mersana’s platform technologies and several cytotoxic agents as conjugates.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

EMD Serono will provide monoclonal antibodies to Mersana. Mersana will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities.

“We have a long-standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients.”

EMD Serono will be responsible for clinical development and commercialisation of any products under an exclusive licence from Mersana. Mersana is eligible to receive milestones plus royalties on worldwide net sales of products in addition to an upfront payment.

EMD Serono translational innovation platform oncology head Dr Andree Blaukat said: “We have a long-standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients.

“Partnering with Mersana allows us to incorporate cutting-edge research and technical excellence to enrich our pipeline.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADCs are composed of an antibody linked to cytotoxic drugs, where the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumour site.